Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

TransMedics Group (TMDX-Q) is a $2.4B stock with a flagship product, the Organ Care System Lung (OCS Lung), designed to treat patients with end-stage lung failure awaiting transplants. Experts recognize the potential regulatory uncertainties, approvals, and competition from companies like FREY, MDT, and CLSN. The company is expected to become profitable in the near future, with excellent historical sales growth. However, it currently trades at a high valuation of 7.7X forward sales, does not generate positive free cash flow, and has a small balance sheet. The consensus seems to be that while the business model is intriguing and there is demand for the technology, the stock carries a high level of risk and its fundamentals have room for improvement.

Consensus
High-Risk
Valuation
Overvalued
Similar
MDT,MDT
BUY
TransMedics Group

They last reported good quarter. He has some knowledge of the organ transplant sector from his charity work, and feels this company is doing well.

medical services
RISKY
TransMedics Group
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

TMDX's flagship product is the Organ Care System Lung (OCS Lung) which can be used to treat patients with end-stage lung failure who are waiting for a lung transplant. It claims that its technology has advantages over the traditional method of placing organs on ice. There are risks of regulatory uncertainties, approvals, and competition from companies like FREY, MDT, CLSN, and others.

The company is a $2.4B stock, which is expected to be profitable over the next year or so, and its historical sales growth rate has been excellent. It has improved its profit margins, but trades at a high valuation of 7.7X forward sales. It does not generate positive free cash flow and has a small balance sheet. We think the name looks interesting, its business model is intriguing and there appears to be demand for the technology, however, its fundamentals could see further improvement. As a more speculative, high-risk play, we would be OK with the name, while considering small-cap risks, position sizing, and the volatility of the underlying industry.
Unlock Premium - Try 5i Free

medical services
BUY
TransMedics Group

Transplant therapy is so vital to America that it transcends the earnings. Likes the story.

medical services
Showing 1 to 3 of 3 entries
  • «
  • 1
  • »

TransMedics Group(TMDX-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 3

Stockchase rating for TransMedics Group is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

TransMedics Group(TMDX-Q) Frequently Asked Questions

What is TransMedics Group stock symbol?

TransMedics Group is a American stock, trading under the symbol TMDX-Q on the NASDAQ (TMDX). It is usually referred to as NASDAQ:TMDX or TMDX-Q

Is TransMedics Group a buy or a sell?

In the last year, 3 stock analysts published opinions about TMDX-Q. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for TransMedics Group.

Is TransMedics Group a good investment or a top pick?

TransMedics Group was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for TransMedics Group.

Why is TransMedics Group stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is TransMedics Group worth watching?

In the last year, there was no coverage of TransMedics Group published on Stockchase.

What is TransMedics Group stock price?

On 2024-02-29, TransMedics Group (TMDX-Q) stock closed at a price of $81.51.